At present most initiated trials are pre-clinical collaborative, this will move to the next phase of P1/11 approved clinical trials this year. I think the outlay of funds for these new trials will take a big chunk of money unless they do a deal to share funding with partners. So basically the smal amount of RnD spending will ramp up once the trials move to the pivotal clinicals...explaining the $$ RnD expenses being low at present.
Market cap is determined by the market..so thats showing a leap of faith in the company potential for oncology treatments, quite a ride this last 12 months. Possibly entering a consolidation phase on market but the news flow has been positive.
link for strategy = https://www.raceoncology.com/race-investor-update-march-2021/
Ann: Quarterly Activity Report & Appendix 4C, page-11
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
0.165(11.5%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.61 | $1.46 | $245.3K | 161.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 229 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.63 | 1226 | 1 |
View Market Depth
| Last trade - 16.10pm 12/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |